Introduction
============

Pancreatic cystic lesions (PCL), are a heterogeneous group of cystic lesions which are divided into two groups: first, mucinous lesions, that include intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN); and non-mucinous lesions (NMN), that include: serous cystic neoplasms (SCN), pseudocysts, cystic neuroendocrine tumors, solid pseudopapillary tumors, and cystic pancreatic ductal adenocarcinomas [@JR1815-1] [@JR1815-2] [@JR1815-3] . All these lesions have diverse clinical, radiological and pathological features. IPMN is the most common [@JR1815-4] .

Frequent use of high-quality cross-sectional imaging has led to a significant increase in the diagnosis of PCLs, however, clinical decision-making remains limited. Magnetic resonance imaging and magnetic resonance cholangiopancreatography are superior to computed tomography in identifying communication between a PCL and the pancreatic duct, the number of PCLs, and presence of a mural nodule [@JR1815-5] . In Spain, a prospective study performed in 298 patients showed that prevalence of unexpected PCLs on endoscopic ultrasound (EUS) is 21.5 %, higher than the prevalence estimates in cross-sectional imaging studies [@JR1815-6] . Currently, the management of PCLs relies on the combination of clinical features, cross-sectional imaging and endoscopic ultrasound with or without fine-needle aspiration (FNA) and fluid analysis. Limitations of these tests are low sensitivity (42 %) [@JR1815-7] ; carcinoembryonic antigen in the cyst fluid has a sensitivity of 52 % to 79 % [@JR1815-5] . FNA plus cytological analysis is a test that can differentiate benign and malign PCLs, but sensitivity is very low. Most importantly, due to the limited accuracy, new diagnostic tools have been introduced to differentiate benign from precancerous and/or malignant PCLs, including EUS-guided through-the-needle forceps biopsy (EUS-TTNB), cyst fluid molecular studies and EUS-guided needle-based confocal laser endomicroscopy (nCLE). The INDEX study showed that EUS with nCLE identified mucinous PCLs with 98 % sensitivity, 94 % specificity, and 97 % accuracy. nCLE was more accurate in classifying mucinous vs nonmucinous cysts than the standard method [@JR1815-8] .

TTNB was first performed by Aparicio et al. in 2010 [@JR1815-9] , in an attempt to improve the diagnostic yield of PCLs. In this report, biopsy forceps and a SpyGlass fiber optic probe were passed through the 19-gauge EUS needle in two patients with a PCL in the head of the pancreas and successfully yielded histology for two PCLs. Currently, novel devices like TTTN Moray microforceps have been developed, and some authors have confirmed in different report cases that it can be useful in determination of histology of PCLs [@JR1815-10] [@JR1815-11] [@JR1815-12] . However, experience with EUS-TTNB for PCLs is still limited, and accordingly, we carried out a systematic review to evaluate the safety and efficacy of this new technique.

Patients and methods
====================

Literature search
-----------------

We performed a systematic review on PubMed, OVID Medline, and Cochrane Databases, by searching for studies published up to October 2019. The search was limited to English-language and human studies, and it was carried out using the following entries: "endoscopic ultrasound," "through-the-needle microforceps biopsy," "Moray microforceps," "pancreatic cystic lesions," "pancreatic cystic neoplasms," and "EUS-guided microbiopsy. Boolean operators (NOT, AND, OR) were also used in succession to narrow and widen the search. Only publications on EUS-TTNB in PCLs were considered, whereas studies with only other cystic evaluations without microforceps biopsy, individual or multiple report cases, duplicates and those with redundant data, review articles or book chapters, commentaries or editorials, non-relevant publications, and alternative techniques of fluid cystic analyses, were excluded and not considered for the present pooled-data analysis ( [Fig. 1](#FI1815-1){ref-type="fig"} ). There was 100 % concordance between reviewers for study selection and data abstraction.

![ Studies identified in the literature.](10-1055-a-1149-1647-i1815ei1){#FI1815-1}

Endpoints
---------

Rates of technical success, adequate specimens, adverse events (AEs), and overall diagnosis were computed. We defined technical success as successful puncture of the pancreatic cyst, subsequent successful mounting of the microbiopsy forceps, and extraction of at least one microbiopsy. The reference standard for overall diagnosis was surgical histopathology in most cases. Adequate specimens were defined as procurement of useful histological results and if the microforceps could be passed through the needle inside the cyst where the jaws of the microforceps were opened and closed to perform the biopsy. Procedure-related AEs were recorded: abdominal pain, fever, acute pancreatitis, extracystic bleeding, and infection. AEs were stratified based in ASGE classification based mainly on need for hospitalization: Mild, events requiring hospitalization of 1 to 3 days; moderate, 4 to 9 days in hospital; severe, more than 10 days in the hospital or needing surgery or intensive care; fatal, death attributable to the procedure [@JR1815-13] .

Data extraction
---------------

Full texts of all selected articles were reviewed to confirm study eligibility. A data extraction form was developed in advance to extract the following information from each study: first author, year of publication, study design, number of patients enrolled, age, gender, PCLs characteristics (site of the lesion, type of the lesion, mean size, multifocality, wall of the lesions), technical success, adequate specimens, adverse events and overall histological diagnosis of pancreatic cysts.

Data analysis
-------------

The percentages and their 95 % confidence intervals (CIs) were calculated for all the considered endpoints. (technical success rate, adverse events rate and overall diagnosis rate). The Greenwood method was used. The Statistical Package for Social Sciences for Windows version 22 (SPSS Inc. Chicago, Illinois, United States) was used to analyze the data.

Results
=======

A flow diagram depicting the search and selection process is provided in [Fig. 1](#FI1815-1){ref-type="fig"} . The initial search yielded 102 articles of which eight studies were finally analyzed [@JR1815-14] [@JR1815-15] [@JR1815-16] [@JR1815-17] [@JR1815-18] [@JR1815-19] [@JR1815-20] [@JR1815-21] .

Characteristics of included studies
-----------------------------------

Characteristics of the eight included studies are listed in [Table 1](#TB1815-1){ref-type="table"} [@JR1815-14] [@JR1815-15] [@JR1815-16] [@JR1815-17] [@JR1815-18] [@JR1815-19] [@JR1815-20] [@JR1815-21] . These studies, comprising 423 patients, were published between 2018 and 2019. Six studies were retrospective and of them, fou rwere multicenter; one was prospective and one was cohort study in design. There were no randomized controlled trials. Mean age of patients ranged from 50.2 to 69.6 years. Of the 423 patients, 172 were male (40.6 %) and 251 were female (59.4 %).

###### Demographic features and PCL characteristics in the different studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                     Number (M/F)   Mean age   PCLs characteristics                                                                                       
  ---------------------------------- -------------- ---------- ---------------------- -------------- ---------------------------- --------- ------------- --------------- --------------
  Barresi L, et al [@JR1815-14]\      56 (17/39)    57.5       Head\                  17 (30.3 %)\   Unilocular 32 (57.1 %)\      38.6 mm   12 (21.4 %)   Thin\           27 (48,2 %)\
  Multicenter\                                                 Neck\                   3 (5,3 %)\    Multilocular 24 (42.8 %)                             Thick\          22 (39,2 %)\
  2018                                                         Body\                  16 (28.5 %)\                                                        Mural nodules   7 (12,5 %)
                                                               Tail\                  13(23.2 %)\                                                                         
                                                               Uncinate                7 (12.5 %)                                                                         

  Basar O, et al [@JR1815-15]\        42 (23/19)    69         Head\                  16 (38.1 %)\   Unilocular 17 (40 %)\        28.2 mm                 Mural Nodules    4 (9.6 %)
  Multicenter\                                                 Body\                  17 (40.5 %)\   Multilocular 25 (60 %)                                               
  2018                                                         Tail                    9 (21.4 %)                                                                         

  Crino S, et al [@JR1815-16]\        61 (14/47)    50.2       Head\                  18 (29.5 %)\   Unilocular 34 (55.7 %)\      40.7 mm                 Thin\           38 (62.2 %)\
  Retrospective\                                               Body\                  23 (37.7 %)\   Multilocular 27 (44.3 %)                             Thick\          20 (32.8 %)\
  2019                                                         Tail                   20 (32.8 %)                                                         Mural nodules    4 (6.6 %)

  Kovacevic B. et al [@JR1815-17]\    28 (13/15)    65         Head\                  11 (39.3 %)\                                30 mm                                   
  Multicenter\                                                 Body\                   9 (32.1 %)\                                                                        
  2018                                                         Tail\                   7 (25.0)%\                                                                         
                                                               Uncinate                1 (3.6 %)                                                                          

  Mittal C, et al [@JR1815-18]\       27 (11/16)    65         Head/uncinate\         14 (51.8 %)\                                37.8 mm                                 
  Retrospective\                                               Body/Tail              13 (48.2 %)                                                                         
  2018                                                                                                                                                                    

  Yang D, et al [@JR1815-19]\         47 (21/26)    66.2       Head\                  16 (34.0 %)\   Unilocular 16 (34.0 %)\      30.8 mm                 Mural nodules    7 (13.5 %)
  Multicenter\                                                 Neck\                   6 (12.8 %)\   Septated 35 (74.5 %)                                                 
  2018                                                         Body\                  13 (27.7 %)\                                                                        
                                                               Tail                   12(25.5 %)                                                                          

  Yang D, et al [@JR1815-20]\        114 (50/64)    64.2       Head\                  31 (27.2 %)\   Unilocular 68 (59.6)\        35.1 mm                 Mural nodule     6 (5.3 %)
  Prospective\                                                 Body\                  44 (38.6 %)\   Septated 36 (31.6)\                                                  
  2019                                                         Tail\                  27 (23.7 %)\   Solid component 7 (6.1)\                                             
                                                               Uncinate\               8 (7.0 %)\    Main PD dilation 8 (7.0 %)                                           
                                                               Not specified           4 (3.5 %)                                                                          

  Zhang M, et al [@JR1815-21]\        48 (23/25)    69.6       Head\                  13 (27.0 %)\                                31 mm                                   
  Cohort study\                                                Neck\                   2 (4.1 %)\                                                                         
  2018                                                         Body\                  20 (41.6 %)\                                                                        
                                                               Tail                   13 (27.0 %)                                                                         
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PCL characteristics
-------------------

PCL characteristics are shown in [Table 1](#TB1815-1){ref-type="table"} . Cysts were located in the head of the pancreas (neck and uncinate were included) in 163 patients (38.5 %), in the body in 142 (33.5 %), and in the tail in 101 (23.8 %). Thirteen cysts (3,.%), were located in the body and/or tail in the study by Mittal et al [@JR1815-18] , without specifying the exact location and no location was specified for four cysts (0.9 %) in the study by Yang et al [@JR1815-20] .

Mean size of cysts was 34.0 mm (mean size ranging of 28.2--40.7 mm). Only five studies specified whether the lesion was uniloculart [@JR1815-13] [@JR1815-14] [@JR1815-15] [@JR1815-18] [@JR1815-19] . In 167 cases (39.4 %), cysts were uniloculated whereas in 147 cases (34.7 %), they were reported as multiloculated or septated; the remainder were not described. A mural nodule was reported in five studies [@JR1815-14] [@JR1815-15] [@JR1815-16] [@JR1815-19] [@JR1815-20] , in total 28 cases (6.6 %) of mural nodules were reported in the different studies.

Technical successful rates
--------------------------

Mean technical success rate in the different studies ranged from 85.7 % to 100 %. In all eight studies, pooled technical success was reported in 95.6 % of cases (399/423), with a 95 % confidence interval (CI) 93.2 % to 97.3 % ( [Fig. 2](#FI1815-2){ref-type="fig"} ). The technical failure rate was reported in 24 cases (5.1 %). Frequency of adequate specimens was 82.2 %, (95 % CI, 78.5 %--85.8 %) reported in seven of eight studies, (mean rate 71.4 %--91.6 %).

![ Pooled analysis assessing rates of technical success of microforceps biopsy in targeting pancreatic cyst lesions. Technical success in targeting pancreatic cysts was 95.6 % (93.2 %--97.3 %; I2 = 82.1 %).](10-1055-a-1149-1647-i1815ei2){#FI1815-2}

Adverse events
--------------

AEs were reported in seven of eight studies. Forty-two total AEs occurred in 375 patients (10.1 % of total cases) (95 % CI, 7.3 %--13.6 %) ( [Fig. 3](#FI1815-3){ref-type="fig"} ). In two studies [@JR1815-18] [@JR1815-19] , there were no AEs. No comment was made about AEs in one study [@JR1815-21] . In 39 patients, AEs were recorded as mild and in three as moderate. No severe or fatal AEs were observed ( [Table 2](#TB1815-2){ref-type="table"} ).

![ Pooled analysis assessing rates of overall diagnosis of microforceps biopsy in targeting pancreatic cyst lesions. Overall diagnosis in targeting pancreatic cysts was 74.6 % (70.2 %--78.7 %; I2 = 87.3 %).](10-1055-a-1149-1647-i1815ei3){#FI1815-3}

###### Results of and adverse events from endoscopic ultrasound-guided through-the-needle forceps biopsy.

  Study                            Technical success rate   Specimen adequacy   Adverse events
  -------------------------------- ------------------------ ------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Barresi L et al [@JR1815-14]      56 (100 %)              47 (83.9 %)         Total 9 (16 %) Grade: Mild: 9 Type of adverse event Abdominal pain: 7 Intracystic hemorrage: 3
  Basar O et al [@JR1815-15]        38 (90.4 %)             30 (71.4 %)         Total 2 (4,7 %) Grade: Mild: 2 Type of adverse event Abdominal pain: 1 Intracystic hemorrage: 1
  Crino S et al [@JR1815-16]        61 (100 %)              91.6 %\*            Total 14 (22.9 %) Grade: Mild: 14 Type of adverse event Transitory fever: 1 Intracystic hemorrage: 10 Mild acute pancreatitis: 2 Peripancreatic bleeding: 1
  Kovacevic B et al [@JR1815-17]    24 (85.7 %)             20 (71.4 %)         Total 3 (10.7 %) Grade: Mild: 1 Moderate: 2 Type of adverse event Abdominal pain: 1 Intracystic hemorrage: 0 Mild acute pancreatitis: 2
  Mittal C et al [@JR1815-18]       27 (100 %)              24 (88.9 %)         Total: 0 (0 %)
  Yang D et al [@JR1815-19]         46 (97.9 %)             40 (85.1 %)         Total: 0 (0 %)
  Yang D et al [@JR1815-20]        111 (97.4 %)             95 (83.3 %)         Total 14 (12.3 %) Grade: Mild: 13 Moderate: 1 Type of adverse event Intracystic hemorrage: 7 Mild acute pancreatitis: 6 Sinus bradycardia: 1 Pseudocyst: 1
  Zhang M et al [@JR1815-21]        36 (75 %)                                   No reported

Overall, of 39 mild adverse events occurred: 20 cases (51.2 %) of intracystic bleeding, 8 cases (20.5 %) of abdominal pain, 7 cases (17.9 %) of mild acute pancreatitis, 1 case (2.5 %) of abdominal pain plus intracystic bleeding, 1 case (2.5 %) of transitory fever, 1 case (2.5 %) of peripancreatic bleeding, 1 case (2.5 %) of sinus bradycardia. All 3 cases of moderate adverse events were mild acute pancreatitis. In the study of Yang et al. [@JR1815-20] , one patient developed a pseudocyst several weeks later that required endoscopic drainage, the patient recovered after stent removal without recurrence.

Overall diagnoses
-----------------

The overall ability to provide a specific diagnosis with EUS-TTNB for diagnosis of pancreatic cystic lesions in all studies was 74.6 % (313 of the 423 cases), 95 % CI: 70.2 %--78.7 %. Mean accuracy among studies ranged from 35.7 % to 88.9 % ( [Fig. 4](#FI1815-4){ref-type="fig"} ).

![ Pooled analysis assessing rates of adverse events of microforceps biopsy in targeting pancreatic cyst lesions. Overall diagnosis in targeting pancreatic cysts was 10.1 % (7.3 %--13.6 %; I2 = 80.13 %)](10-1055-a-1149-1647-i1815ei4){#FI1815-4}

The most frequent diagnoses found with EUS-TTNB were: MCN in 96 cases (30.6 %), intraductal papillary mucinous neoplasm in 80 cases (25.5 %), and SCN in 48 cases (15.3 %). In [Table 3](#TB1815-3){ref-type="table"} and [Table 4](#TB1815-4){ref-type="table"} , detailed diagnoses obtained by EUS-TTNB in all the studies are reported.

###### EUS-TTNB diagnosis in different studies.

  Study                               Overall diagnosis   EUS TTNB diagnosis    
  ----------------------------------- ------------------- --------------------- -------------
  Barresi L et al [@JR1815-14]        47 (83.9 %)         Serous cystoadenoma   14 (29.7 %)
  BD-IPMN                             10 (21.2 %)                               
  Cystic mucinous neoplasm             8 (17 %)                                 
  Pseudocyst                           7 (14.8 %)                               
  No definite mucinous cyst            4 (8.5 %)                                
  Malignant cystic neoplasm            3 (6.3 %)                                
  Other                                1 (2.1 %)                                
  Basar O. et al [@JR1815-15]         15 (35.7 %)         Serous cystoadenoma    3 (20 %)
  BD-IPMN                              6 (40 %)                                 
  Cystic mucinous neoplasm             2 (13.3 %)                               
  Adenocarcinoma                       2 (13.3 %)                               
  cPNET                                1 (6.6 %)                                
  Acinar cystoadenoma                  1 (6.6 %)                                
  Crino S et al [@JR1815-16]          50 (81.9 %)         Serous cystoadenoma   13 (21.3 %)
  BD-IPMN                              7 (11.5 %)                               
  Cystic mucinous neoplasm            14 (22.9 %)                               
  Pseudocyst                           2 (3.3 %)                                
  Neuroendocrine tumors                5 (8.2 %)                                
  Squamoid cyst                        3 (4.9 %)                                
  Lymphangioma                         2 (3.3 %)                                
  Mucinous non-neoplastic cyst         2 (3.3 %)                                
  Lymphoepithelial cyst                1 (1.6 %)                                
  Solid pseudopapillary neoplasm       1 (1.6 %)                                
  No definite                         11 (18 %)                                 
  Kovacevic B et al [@JR1815-17]      19 of 24 (79.1 %)   Serous Cystoadenoma   2 (8.3 %)
  BD-IPMN                             13 (54.1 %)                               
  Cystic mucinous neoplasm             1 (4.2 %)                                
  Pseudocyst                           1 (4.2 %)                                
  Neuroendocrine tumors                2 (8.3 %)                                
  MCN associated carcinoma             1 (4.2 %)                                
  Insufficient material                1 (4.2 %)                                
  Inconclusive                         3 (12.5 %)                               
  Mittal C et al [@JR1815-18]         24 (88.9 %)         Serous cystoadenoma    4 (14.8 %)
  BD-IPMN                              0 (0 %)                                  
  Cystic mucinous neoplasm             9 (33.3 %)                               
  Benign / Inflammatory               10 (37.1 %)                               
  Neuroendocrine tumors                1 (3.7 %)                                
  Yang D et al [@JR1815-19]           39 (82.9 %)         Serous cystoadenoma    4 (8.5 %)
  Cystic mucinous neoplasm            26 (55.3 %)                               
  Benign fibrous tissue                7 (14.9 %)                               
  Inflammatory cells                   2 (4.2 %)                                
  Yang D et al [@JR1815-20]           95 (88.9 %)         Serous cystoadenoma    5 (4.3 %)
  Mucinous cyst                       61 (53.5 %)                               
  Mucinous cyst with adenocarcinoma    2 (1.7 %)                                
  Inflammatory                        14 (12.2 %)                               
  Benign glandular cells               6 (5.2 %)                                
  Solid pseudopapillary tumor          1 (0.8 %)                                
  Cystic neuroendocrine tumor          6 (5.2 %)                                
  Zhang M et al [@JR1815-21]          24 (50 %)           Serous cstoadenoma     3 (6.3 %)
  BD-IPMN                             18 (37.5 %)                               
  Mucinous cystic neoplasm             1 (2.1 %)                                
  Adenocarcinoma                       1 (2.1 %)                                
  Acinar cystoadenoma                  1 (2.1 %)                                

EUS-TTNB, endoscopic ultrasound-guided through-the-needle forceps biopsy; BD-IPMN, bile

duct papillary mucinous neoplasm.

###### Overall diagnosis of PCLs in studies of EUS-TTNB.

  Diagnosis                         Barresi L, et al [@JR1815-13]   Basar O, et al [@JR1815-14]   Crino S, et al [@JR1815-15]   Kovacevic B. et al [@JR1815-16]   Mittal C, et al [@JR1815-17]   Yang D, et al [@JR1815-18]   Yang D, et al [@JR1815-19]   Zhang M, et al [@JR1815-20]   Total   \%
  --------------------------------- ------------------------------- ----------------------------- ----------------------------- --------------------------------- ------------------------------ ---------------------------- ---------------------------- ----------------------------- ------- -------
  Serous cystoadenoma neoplasm      14                               3                            13                             2                                 4                              4                            5                           3                              48     15.34
  IPMN                              10                               6                             7                            13                                                               26                                                        18                             80     25.56
  Mucinous cystic neoplasm           8                               2                            14                             1                                 9                                                          61                           1                              96     30.67
  Pseudocyst                         7                                                             2                             1                                                                                                                                                         9     2.88
  Malignant cystic neoplasm          3                                                                                           1                                                                                             2                                                           6     1.92
  Adenocarcinoma                                                     2                                                           1                                                                                             2                           1                               3     0.96
  Neuroendocrine pancreatic tumor                                    1                             5                             2                                 1                                                           6                                                          15     4.79
  Acinar cystoadenoma                                                1                                                                                                                                                                                     1                               2     0.64
  Squamoid cyst                                                                                    3                                                                                                                                                                                       3     0.96
  Lymphangioma                                                                                     2                                                                                                                                                                                       2     0.64
  Mucinous non-neoplastic cyst                                                                     2                                                                                                                                                                                       2     0.64
  Lymphoephitelial cyst                                                                            1                                                                                                                                                                                       1     0.32
  Solid pseudopapillary Neoplasm                                                                   1                                                                                                                           1                                                           2     0.64
  No definite mucinous cyst          4                                                                                                                                                                                                                                                     4     1.28
  Benign/inflammatory                                                                                                                                             10                              9                           20                                                          39     12.46
  Other                              1                                                                                                                                                                                                                                                     1     0.32
  No definite diagnosis                                                                           11                             3                                                                                                                                                        14     4.47
  Total                             47                              15                            50                            19                                24                             39                           95                           24                            313     100

PCL, pancreatic cystic lesion; EUS-TTNB, endoscopic ultrasound-guided through-through-needle forceps biopsy; IPMN, intraductal papillary mucinous neoplasm.

Discussion
==========

It has been acknowledged that some patients with PCLs have a significantly higher overall risk of pancreatic cancer [@JR1815-22] , and actually, the frequent use of high-quality cross-sectional imaging has led to a significant rise in diagnosis of PCLs. In the meta-analysis of Zerboni G, et al in 2019, prevalence of PCLs in asymptomatic individuals was 8 % [@JR1815-23] , while incidence of these lesions increases with age and reaches 37 % in patients older than 80 [@JR1815-24] . In Spain, a prospective study performed in 298 patients, the authors recorded that incidental prevalence of pancreatic cysts on EUS (21.5 %) was higher than prevalence estimates in cross-sectional imaging studies [@JR1815-6] . Surgery is currently considered the standard of care for malignant and high-risk premalignant PCLs. At present, the great problem is optimization of diagnostic tools, and given their accuracy, patients may be overtreated with surgery, or to the contrary, may not be kept under surveillance when they should be. Actually, EUS-TTNB is a technique that allows targeted tissue acquisition of the PCLs. We performed a systematic review literature with pooled data analysis of available studies to evaluate performance of EUS-TTNB for diagnosis of pancreatic cystic lesions.

All authors used a standard technique. An oblique/forward-viewing therapeutic linear array echoendoscope was used to visualize the PCLs. The cyst was then punctured by using a 19-gauge EUS-FNA needle, with a stylet. A transgastric or trasduodenal approach was used for PCLs, the stylet was removed, and a biopsy of the wall of the cyst was done by using the microforceps passed through the 19-gauge needle under direct EUS visualization. The open jaws of the forceps were pushed onto the cyst wall, closed and pulled back to cause visible tenting. The forceps were then "plucked" and removed from the patient, leaving the 19-gauge needle in the cyst. Crino et al. [@JR1815-16] , found that a mean number of 3.25 passes per patient was necessary to obtain 3 visible histologic specimens, which were judged to be adequate for histologic evaluation in approximately 92 % and performed one "bite" per pass from observing the "tent sign" of the cystic wall, which theoretically demonstrates an effective grip of the microforceps on the wall. With the protocol of Crino et al, they reached 100 % histologic adequacy after two biopsy samples. Yang et al [@JR1815-19] , performed three bites per pass for a total of three passes, obtaining a histologic sample in only 83 % of the cases.

Since the first case reported by Aparicio et al, [@JR1815-9] in 2010, many case reports have been published [@JR1815-11] [@JR1815-25] [@JR1815-26] [@JR1815-27] [@JR1815-28] [@JR1815-29] [@JR1815-30] . We collected data from eight studies, with the first published in 2018, overall including 423 patients. In this systematic review, we have observed a predominance of PCLs in women, in seven of eight studies, (ratio F:M of 1.5:1) whereas the mean age of patients was 63.3 years and was similar in different series (ranging from 50.2 to 69.6 years). The site of the PCLs was distributed differently and heterogeneously in the different studies, however, pooled analysis data show that the most frequent location was in the head of the pancreas (38.5 %). In our analysis, pancreatic neck and uncinated process were included in this group, because some authors do not discriminate or differentiate between these locations individually. Only Barresi L et al [@JR1815-14] noted distribution of lesions in five regions (head, neck, body, tail and uncinated).

Lesion type was reported in five of eight studies [@JR1815-14] [@JR1815-15] [@JR1815-16] [@JR1815-19] [@JR1815-20] , with unilocular being the most frequently reported (39.4 %). In three studies, [@JR1815-15] [@JR1815-16] [@JR1815-19] , no statistically significant relationship was found between cyst features or biopsy sampling route and the diagnostic yield of two TTNB-EUS specimens, except for a lower capability to retrieve the cyst epithelial lining in lesions located in the pancreatic tail. Mean size of PCLs was 34.0 mm and was similar in different series (ranging from 28.2 to 40.7 mm). Only Barresi L et al [@JR1815-14] reported 12 cases (21.4 %) of multifocality of cysts in their study.

According to the recent European guidelines [@JR1815-5] , presence of an enhancing mural nodule (≥ 5 mm) is an absolute indication for surgery; patients with mucinous cystic neoplasm ≥ 40 mm should undergo surgical resection if a mural nodule exists irrespective of their size [@JR1815-5] [@JR1815-30] . In this systematic review, we found that five of eight studies recorded presence of the mural nodule [@JR1815-14] [@JR1815-15] [@JR1815-16] [@JR1815-19] [@JR1815-20] , in total, 28 cases of mural nodule were reported.

Timing of the procedures was assessed only in the study by Kovacevic et al [@JR1815-17] , they reported a mean procedural time of 32 minutes, with a mean of three biopsy samplings performed.

In all eight studies, encouraging results were reported in terms of both technical success and diagnostic yield. The technical success rate was 95.6 % (399 of 423 cases), with a mean technical success rate ranging from 85.7 % to 100 % in the different studies, whereas the technical failure rate was reported in 24 cases (5.1 %). The overall ability to provide a specific diagnosis with EUS-TTNB for diagnosis of pancreatic cystic lesions in all studies was 74.6 % (313 of 423 cases). The mean rate ranged from 35.7 % to 88.9 %. However, the arguments to explain the advantage of TTNB on cytology are also problems for TTNB (heterogeneity of presence of epithelium in mucinous cystic neoplasm, IPMN or neuroendocrine neoplasm) and one limit of TTNB is inability to check a large part of the wall. That is may explain why diagnosis with TTNB, overall, is imperfect.

Technical failure seems to be caused by loss of flexibility of the echoendoscope when both forceps and the FNA needle are inserted. Other technical difficulties described did not hinder procurement of specimens. Failures were seen in locations where EUS‑guided puncture is known to be challenging, i. e., when the echoendoscope was placed in the duodenum [@JR1815-16] . In the study by Barresi et al [@JR1815-14] , specimens were considered adequate for histological diagnosis in 47 of 56 (83.9 %; 95 % CI, 72 %--92 %). In two of these patients, despite histological adequacy, a diagnosis could not be reached. In the other two cases, a specimen sufficient for cytological diagnosis was obtained. Basar et al [@JR1815-15] reported that pinch biopsy specimen was insufficient for histology processing in four of 42 patients (9.6 %), two from a cyst wall and two from a septum. Crino et al [@JR1815-16] , reported that inadequacy was because of clots in 10 cases and amorphous material in five cases. Mittal et al [@JR1815-18] no reported procedural difficulty, but microforceps biopsies did not provide a pathologic diagnosis in three cases because tissue obtained with the microforceps biopsy was not adequate for pathologic diagnosis. Kovacevic et al [@JR1815-17] reported technical failure in four patients, due to inability to access the cyst while the echoendoscope was maximally flexed, and observation of lesions located in the head (3 cases) and the tail (1 case) of the pancreas, the latter with failed transgastric puncture.

The most frequent diagnoses found with EUS-TTNB were: mucinous cystic neoplasms in 96 cases (30.6 %), IPMN in 80 cases (25.5 %), and serous cystoadenoma neoplasm in 48 cases (15.3 %). Distinguishing between a serous and mucinous cystic neoplasm is important because all mucinous cystic neoplasms are resected regardless of grade because of the ease of the usual distal pancreatectomy compared with the expense and anxiety of life-long surveillance for progression to malignancy in the typical middle-aged woman [@JR1815-31] . Conversely, branch duct IPMNs without high-risk features behave in a benign fashion and occur mostly in elderly patients, thereby supporting a conservative management approach [@JR1815-21] . Therefore, determining cyst type as well as the malignant potential of a cyst dictates the best treatment strategy while avoiding unnecessary surgery. Furthermore, TTNB has advantages over cytology alone, the latter is insufficient for diagnosis in up to 60 % of patients because of the absence of epithelial cells in cyst fluid, presence of gastrointestinal contamination, heterogeneity of mucinous cyst dysplasia, and lack of experience and expertise in cytologic interpretation [@JR1815-32] [@JR1815-33] [@JR1815-34] [@JR1815-35] . In addition, the fragile cells of serous cystadenoma rarely survive processing for diagnosis, and the subepithelial ovarian-type stroma required for diagnosis of MCN is not present in aspirated cyst fluid. Conversely, TTNB provides tissue from the cyst wall, septations, and mural nodules for histology, thus providing tissue for ancillary studies such as immunohistochemistry, and the distinction between these two types of mucinous cysts was only possible with the addition of TTNB. It would be interesting to study whether TTNB can be useful for diagnosing the histological type of IPMN, but none of the eight studies mention it. In conclusion, our systematic review showed that the effectivenes of TTNB-EUS was not affected by size, location, or septations in cysts and provided a specific diagnosis for the subtype of pancreatic cyst.

Forty-two total AEs in 375 patients (10.1 % of total cases), 39 patients were recorded as mild AEs and three as moderate AEs. No severe or fatal AEs were observed. Barresi et al [@JR1815-14] reported that intracystic bleeding from the sites of micro-biopsy in the cystic wall was the most common AE observed, and was self-limited in all cases. Basar et al [@JR1815-15] , do not observed serious AEs. Only one patient had mild abdominal pain, which lasted for an hour after the procedure. Another patient had self-limited intracystic bleeding, which did not progress and did not result in any symptoms. Crino et al [@JR1815-16] observed a case of transitory fever with possible cyst infection, which resolved with conservative treatment without the need for hospital admission. In this cohort, they observed an overall AEs rate of 22.9 %, with a slight increase in intracystic bleeding (16.4 %). In all cases, bleeding was self-limiting and asymptomatic and did not require medical intervention. Three moderate AEs were recorded, two by Kovacevic et al [@JR1815-17] and one by Yang et al [@JR1815-20] . All were mild acute pancreatitis. Two patients were hospitalized for 4 and 6 days, respectively. They were treated with intravenous fluids and analgesics and recovered completely [@JR1815-17] . Yang et al [@JR1815-20] reported six patients with postprocedural acute pancreatitis based on laboratories and imaging, and abdominal pain within 12 to 24 hours after the EUS, nearly all of these episodes were mild (5 of 6); three patients required hospitalization. Two of these patients were discharged within 24 to 48 hours with supportive care and subsequently followed up in the clinic without any sequelae. One patient developed a pseudocyst several weeks later that required endoscopic drainage. The patient recovered after stent removal without recurrence. Limitations of our study, are mainly based on the fact that unfortunate issues with study centers handing out data to multiple studies, hence, a systemic review or meta-analysis is never accurate unless the authors disclose the data and account for redundancy from each of these study centers.

The current status of new technologies for evaluation of PCLs includes confocal endomicroscopy and molecular markers. Both EUS-nCLE and cyst fluid molecular analysis of PCLs represent promising new modalities to improve the diagnostic evaluation of PCLs. EUS with nCLE identified mucinous PCLs with 98 % sensitivity, 94 % specificity, and 97 % accuracy. nCLE was more accurate in classifying mucinous vs nonmucinous cysts than the standard method. In clinical practice, these technologies may be particularly useful in cases with diagnostic uncertainty so as to improve accuracy and allow for appropriate risk stratification [@JR1815-1] .

Conclusion
==========

In our systematic review, we observed that TTNB appears to be effective and safe, with few AEs for diagnosis of pancreatic cystic lesions. The technique had acceptable rates of technical and clinical success and an excellent safety profile. TTNB is associated with a high tissue acquisition yield and provided additional diagnostic yield for mucinous pancreatic lesions. We think that TTNB may be a useful adjunctive tool for EUS-guided assessment of PCLs, complementing existing EUS-FNA sampling protocols. Future prospective studies and randomized controlled trials are needed to further validate our initial findings and the type of cysts in which this procedure should be performed.
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